SGS North America Announces Expansion of Biologics Testing Capabilities
CHICAGO, July 2, 2024 /PRNewswire/ – SGS North America (SGS) announced today that it has added new capacity and capabilities to bolster its biologics testing... Read more.
SiriusXM to Report Second Quarter 2024 Operating and Financial Results
NEW YORK, July 2, 2024 /PRNewswire/ — SiriusXM (NASDAQ: SIRI) today announced plans to release its second quarter 2024 operating and financial results on Thursday,... Read more.
SiriusXM to Report Second Quarter 2024 Operating and Financial Results
NEW YORK, July 2, 2024 /PRNewswire/ — SiriusXM (NASDAQ: SIRI) today announced plans to release its second quarter 2024 operating and financial results on Thursday,... Read more.
Cboe Global Markets Announces Date of Second-Quarter 2024 Earnings Release and Conference Call
CHICAGO, July 2, 2024 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), the world’s leading derivatives and securities exchange network, will... Read more.
Cboe Global Markets Announces Date of Second-Quarter 2024 Earnings Release and Conference Call
CHICAGO, July 2, 2024 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), the world’s leading derivatives and securities exchange network, will... Read more.
FDA Roundup: July 2, 2024
SILVER SPRING, Md., July 2, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the... Read more.
KLA Announces Fourth Quarter Fiscal Year 2024 Earnings Date
MILPITAS, Calif., July 2, 2024 /PRNewswire/ — KLA Corporation (NASDAQ: KLAC) today announced that the company will review fourth quarter fiscal year 2024... Read more.
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised... Read more.
AAR to announce fourth quarter fiscal year 2024 results on July 18, 2024
WOOD DALE, Ill., July 2, 2024 /PRNewswire/ — AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and... Read more.
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
– In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein– -TYRA remains on track... Read more.